Abstracts tagged "Treatment options"

Abstract Number: 1529 • 2019 ACR/ARP Annual Meeting
The Efficacy and Safety of Anti-TNFα Treatment in Ankylosing Spondylitis Patients with Late Onset Compared to Those with Adult Onset; The Data from TURKBIO Registry
Sadettin Uslu¹, Gercek Can ², Ayşe Cefle ³, Sema Yılmaz ⁴, Sinem Burcu Kocaer ⁵, Tuba Yüce İnel ¹, Semih Gülle ¹, Süleyman Serdar Koca ⁶, Servet Yolbaş ⁷, Mehmet Akif Öztürk ⁸, Soner Senel ⁹, Nevsun Inanc ¹⁰, Ediz Dalkılıç ¹¹, Ozgül Gunduz ¹², Abdurrahman Tufan ⁸, Servet Akar ¹³, Merih Birlik ⁵, Ismail Sari ¹, Nurullah Akkoç ¹² and Fatos Onen ¹⁴, ¹Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Izmir, Turkey, ²Dokuz Eylul University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Izmir, Turkey, ³Division of Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ⁴Division of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, Konya, Turkey, ⁵Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Turkey,Izmir, Izmir, Turkey, ⁶Fırat University School of Medicine Division of Rheumatology, Elazığ, Turkey, ⁷Division of Rheumatology, Inonu University School of Medicine, Malatya, Turkey, Malatya, Turkey, ⁸Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey, Ankara, Turkey, ⁹Division of Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, Kayseri, Turkey, ¹⁰Marmara University, Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ISTANBUL, Turkey, ¹¹Uludağ University, Bursa, Turkey, ¹²Division of Rheumatology, Celal Bayar University School of Medicine, Manisa, Turkey, Manisa, Turkey, ¹³Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁴Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey
Background/Purpose: The first symptoms of ankylosing spondylitis (AS) patients usually begin prior to 45 years, but can occur later in life. The purpose of this…
Abstract Number: 2193 • 2019 ACR/ARP Annual Meeting
“If It Was Unicorn Dust I’d Have It Again.” Patient Experiences of Hip Osteoarthritis and Treatments in the Hip Injection Trial
Clare Jinks ¹, Ashley Hawarden ¹, Edward Roddy², Zoe Paskins ³, Christian Mallen ⁴ and Melanie Holden ⁵, ¹Research Institute for Primary Care and Health Sciences, Keele University, Keele, England, United Kingdom, ²Research Institute for Primary Care and Health Sciences and Keele Clinical Trials Unit, Keele, United Kingdom, ³Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, ⁴Research Institute for Primary Care and Health Sciences, Keele University, UK, Keele, United Kingdom, ⁵Research Institute for Primary Care and Health Sciences and Keele CTU, Keele University, Keele, England, United Kingdom
Background/Purpose: Evidence of the effectiveness of intra-articular corticosteroid injection for hip osteoarthritis (OA) is limited and conflicting. The HIT trial compared the clinical effectiveness of…
Abstract Number: 10L • 2015 ACR/ARHP Annual Meeting
Aiming for Remission in Rheumatoid Arthritis: Clinical and Radiographic Outcomes from a Randomized Controlled Strategy Trial Investigating the Added Value of Ultrasonography in a Treat-to-Target Regimen
Espen A. Haavardsholm¹, Anna-Birgitte Aga¹, Inge C Olsen², Hilde B. Hammer³, Till Uhlig⁴, Hallvard Fremstad⁵, Tor Magne Madland⁶, Åse S. Lexberg⁷, Hilde Haukeland⁸, Erik Rødevand⁹, Christian Høili¹⁰, Hilde Stray¹¹, Anne Noraas Bendvold¹², Inger Johanne Widding Hansen¹³, Gunnstein Bakland^14,15, Lena B. Nordberg¹, Siri Lillegraven¹, Désirée van der Heijde^1,16 and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Dept. of Rheumatology, Ålesund Hospital, Helse Møre og Romsdal HF, Ålesund, Norway, ⁶Dept. of Rheumatology, Haukeland University Hospital, Bergen, Norway, ⁷Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁸Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁹Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ¹⁰Dept. of Rheumatology, Hospital Østfold HF, Moss, Norway, ¹¹Haugesund Rheumatism Hospital, Haugesund, Norway, ¹²The Rheumatology Clinic Dovland/Bendvold, Kristiansand, Norway, ¹³Dept. of Rheumatology, Sørlandet Hospital, Kristiansand, Norway, ¹⁴Dept. of Rheumatology, University Hospital Northern Norway, Tromsø, Norway, ¹⁵Institute of Clinical Medicine, University Hospital of North Norway, Tromsø, Norway, ¹⁶Dept. of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The application of ultrasonography (US) in rheumatology clinical practice is growing. The ARCTIC trial (NCT01205854) was designed to examine if the use of a…
Abstract Number: 1299 • 2012 ACR/ARHP Annual Meeting
Rituximab Versus Abatacept in Rheumatoid Arthritis Patients with an Inadequate Response to Prior Biologic Therapy: A Retrospective, Single-Center Study
Edward Keystone¹, Juan Xiong², Deborah Weber³ and Ye Sun⁴, ¹The Rebecca MacDonald Centre for Arthritis and Autoimmunity, Mount Sinai Hospital, Toronto, ON, Canada, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Mount Sinai Hospital, Toronto, ON, Canada, ⁴Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Patients with RA who experience an inadequate response to TNF inhibitor (TNFi) therapy (TNF-IR) may be successfully treated using an alternative TNFi or a…
Abstract Number: 456 • 2012 ACR/ARHP Annual Meeting
Factors Influencing Choice of Rituximab Versus an Alternative Tumor Necrosis Factor Inhibitor Following Tumor Necrosis Factor Inhibitor Failure in Patients with Rheumatoid Arthritis: Sub-Analysis of a Global, Observational Comparative Effectiveness Study
Axel Finckh¹, Jacques-Eric Gottenberg², Chiedzo Mpofu³, William G. Bensen⁴, Andrea Rubbert-Roth⁵, Fedra Irazoque⁶, Victor Martínez Taboada⁷, Carol Chung⁸, Lykke Hinsch-Gylvin³, Clodoveo Ferri⁹ and Paul Emery¹⁰, ¹Department of Internal Medicine, University Hospital of Geneva, Geneva, Switzerland, ²Strasbourg University Hospital, Strasbourg, France, ³F Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁵Internal Medicine I, University of Cologne, Cologne, Germany, ⁶Servicio de Reumatología, Hospital Angeles Mocel, Mexico City, Mexico, ⁷Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁸Genentech Inc., South San Francisco, CA, ⁹Department of Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy, ¹⁰Division of Rheumatic & Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom
Background/Purpose: SWITCH-RA is a global, observational study evaluating the effectiveness of switching to an alternative TNFi or rituximab (RTX) following initial TNFi failure in patients…
Abstract Number: 464 • 2012 ACR/ARHP Annual Meeting
Rituximab for Treatment of Rheumatoid Arthritis: Treatment Effectiveness in the Corrona Database
Leslie R. Harrold¹, George W. Reed¹, Robert P. Magner¹, Katherine C. Saunders², Jeffrey D. Greenberg³, Joel M. Kremer⁴, Ani John⁵, William Reiss⁵, Steve Zlotnick⁶ and Ashwini Shewade⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC., Southborough, MA, ³New York Hospital for Joint Disease, New York, NY, ⁴Center for Rheumatology, Albany Medical College, Albany, NY, ⁵Genentech Inc., South San Francisco, CA, ⁶Genentech, Inc., a Member of the Roche Group, South San Francisco, CA
Background/Purpose: Rituximab (RTX) in combination with methotrexate is used for the treatment of adult RA with an inadequate response to TNF antagonists. We aimed to…
Abstract Number: 467 • 2012 ACR/ARHP Annual Meeting
Seropositive Rheumatoid Arthritis Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors Achieve Improved Clinical Effectiveness After Switching to Rituximab Versus Switching to an Alternative Tumor Necrosis Factor Inhibitor
Andrea Rubbert-Roth¹, Axel Finckh², Piercarlo Sarzi-Puttini³, Jacques-Eric Gottenberg⁴, Denis Choquette⁵, Victor Martínez Taboada⁶, Leonor Barile-Fabris⁷, Carol Chung⁸, Lykke Hinsch-Gylvin⁹ and Paul Emery¹⁰, ¹Internal Medicine I, University of Cologne, Cologne, Germany, ²Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ³Rheumatology Unit, L Sacco University Hospital, Milan, Italy, ⁴Strasbourg University Hospital, Strasbourg, France, ⁵Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁶Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Instituto Mexicano del Seguro Social, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Mexico City, Mexico, ⁸Genentech Inc., South San Francisco, CA, ⁹F Hoffmann-La Roche Ltd, Basel, Switzerland, ¹⁰Division of Rheumatic & Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom
Background/Purpose: RA patients (pts) with an inadequate response (IR) to a tumor necrosis factor inhibitor (TNFi) may achieve greater benefit by switching to rituximab (RTX)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].